三生国健与辉瑞签署的许可协议正式生效

财中社
24 Jul

7月24日,三生国健(688336)发布公告,近日与辉瑞公司签署的许可协议正式生效。此次交易涉及三生国健及其关联方三生制药和沈阳三生,协议中规定辉瑞将获得在中国大陆独家开发和商业化707项目的选择权。根据《中国大陆选择权协议》,辉瑞需支付的期权金和行权金合计不超过1.5亿美元,且不可退还或抵扣。此外,公告提到,三生国健与沈阳三生的利益分配比例将继续按照30%和70%进行。此次交易被认定为关联交易,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10